Regencell Bioscience (RGC) Competitors $15.05 -0.13 (-0.86%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGC vs. BNTX, SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, and ASNDShould you be buying Regencell Bioscience stock or one of its competitors? The main competitors of Regencell Bioscience include BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Regencell Bioscience vs. Its Competitors BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Regencell Bioscience (NASDAQ:RGC) and BioNTech (NASDAQ:BNTX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation. Is RGC or BNTX more profitable? Regencell Bioscience has a net margin of 0.00% compared to BioNTech's net margin of -27.37%. Regencell Bioscience's return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets Regencell BioscienceN/A N/A N/A BioNTech -27.37%-3.94%-3.41% Does the media refer more to RGC or BNTX? In the previous week, BioNTech had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for BioNTech and 3 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.19 beat BioNTech's score of 0.51 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, RGC or BNTX? Regencell Bioscience has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Which has higher earnings and valuation, RGC or BNTX? Regencell Bioscience has higher earnings, but lower revenue than BioNTech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegencell BioscienceN/AN/A-$4.30MN/AN/ABioNTech$2.75B10.09-$719.92M-$3.40-33.91 Is RGC or BNTX a better dividend stock? Regencell Bioscience pays an annual dividend of $0.88 per share and has a dividend yield of 5.8%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.3%. BioNTech pays out -45.0% of its earnings in the form of a dividend. Do insiders & institutionals believe in RGC or BNTX? 0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer RGC or BNTX? BioNTech has a consensus price target of $136.58, indicating a potential upside of 18.45%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummaryBioNTech beats Regencell Bioscience on 9 of the 16 factors compared between the two stocks. Get Regencell Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for RGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGC vs. The Competition Export to ExcelMetricRegencell BioscienceMedicinal Chemicals IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$7.51B$7.51B$2.27B$9.50BDividend YieldN/AN/A2.57%4.00%P/E RatioN/AN/A22.0720.08Price / SalesN/AN/A80.1989.31Price / CashN/AN/A29.1858.56Price / Book752.50752.5055.705.88Net Income-$4.30M-$4.30M-$121.61M$258.89M7 Day Performance3.79%3.79%0.95%3.71%1 Month Performance-25.46%-25.46%2.11%11.72%1 Year PerformanceN/AN/A25.27%18.01% Regencell Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGCRegencell Bioscience0.2407 of 5 stars$15.05-0.9%N/AN/A$7.51BN/A0.0010Positive NewsBNTXBioNTech1.428 of 5 stars$114.38+2.6%$136.58+19.4%+36.2%$27.53B$2.75B-33.686,772News CoverageSMMTSummit Therapeutics2.5068 of 5 stars$27.74+4.5%$34.67+25.0%+173.3%$20.61B$700K-81.63110Positive NewsINSMInsmed3.927 of 5 stars$102.14-0.8%$109.20+6.9%+39.5%$19.44B$363.71M-17.221,271News CoverageAnalyst ForecastInsider TradeTEVATeva Pharmaceutical Industries4.0149 of 5 stars$16.59+1.8%$24.71+49.0%-1.6%$19.11B$16.54B-14.4936,830Upcoming EarningsAnalyst UpgradeGMABGenmab A/S4.0859 of 5 stars$22.87+4.9%$37.80+65.3%-16.8%$14.68B$3.12B13.002,682Gap UpMRNAModerna4.3013 of 5 stars$35.08+7.2%$46.11+31.4%-71.6%$13.57B$3.14B-4.025,800Upcoming EarningsAnalyst ForecastRDYDr. Reddy's Laboratories2.7396 of 5 stars$14.73+2.2%$16.95+15.1%-9.3%$12.28B$3.81B22.2827,811Earnings ReportQGENQiagen3.6745 of 5 stars$50.34+1.7%$49.40-1.9%+26.1%$11.20B$1.98B126.335,765Analyst DowngradeAnalyst RevisionVTRSViatris2.4298 of 5 stars$9.40+1.7%$10.40+10.7%-20.0%$11.03B$14.33B-2.9632,000ASNDAscendis Pharma A/S3.436 of 5 stars$168.21+1.6%$223.07+32.6%+24.6%$10.30B$393.54M-26.821,017Positive NewsAnalyst Revision Related Companies and Tools Related Companies BNTX Competitors SMMT Competitors INSM Competitors TEVA Competitors GMAB Competitors MRNA Competitors RDY Competitors QGEN Competitors VTRS Competitors ASND Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGC) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGC Stock Alerts